FRM
GSK icon

Fox Run Management’s GSK GSK Stock Holding History

Fox Run Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,763
Closed -$720K – 1043
2025
Q2 		$720K Sell
18,763
-17,021
-48% -$650K 0.12% 315
2025
Q1 		$1.39M Buy
+35,784
New +$1.31M 0.21% 96
2024
Q4 		– Sell
-17,073
Closed -$698K – 992
2024
Q3 		$698K Sell
17,073
-20,950
-55% -$857K 0.16% 234
2024
Q2 		$1.46M Buy
38,023
+31,733
+504% +$1.33M 0.28% 71
2024
Q1 		$270K Sell
6,290
-27,134
-81% -$1.12M 0.06% 562
2023
Q4 		$1.24M Buy
33,424
+22,444
+204% +$806K 0.32% 42
2023
Q3 		$398K Buy
+10,980
New +$390K 0.12% 344
2022
Q3 		– Sell
-5,989
Closed -$326K – 699
2022
Q2 		$326K Buy
+5,989
New +$331K 0.16% 260
2022
Q1 		– Sell
-8,502
Closed -$469K – 588
2021
Q4 		$469K Buy
+8,502
New +$442K 0.28% 96
2021
Q3 		– Sell
-5,555
Closed -$277K – 535
2021
Q2 		$277K Buy
+5,555
New +$267K 0.25% 193
2021
Q1 		– Sell
-6,734
Closed -$310K – 255
2020
Q4 		$310K Buy
+6,734
New +$309K 0.63% 43
2019
Q4 		– Sell
-6,850
Closed -$365K – 446
2019
Q3 		$365K Buy
+6,850
New +$352K 0.33% 100
2018
Q3 		– Sell
-4,188
Closed -$211K – 671
2018
Q2 		$211K Sell
4,188
-6
-0.1% -$302 0.07% 568
2018
Q1 		$205K Sell
4,194
-1,717
-29% -$80K 0.05% 624
2017
Q4 		$262K Buy
+5,911
New +$273K 0.08% 503
2017
Q2 		– Sell
-12,320
Closed -$649K – 700
2017
Q1 		$649K Buy
+12,320
New +$625K 0.26% 103
2016
Q3 		– Sell
-7,280
Closed -$394K – 562
2016
Q2 		$394K Buy
+7,280
New +$384K 0.19% 190

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fox Run Management's GSK Position: Q3 2025 in Review

Fox Run Management sold out of GSK (GSK) in Q3 2025, closing a stake of 18,763 shares — an estimated $720K sold.

Fox Run Management first reported a position in GSK in Q2 2016 and held it in 17 quarters. The position peaked at $1.46M in Q2 2024. 895 funds tracked by Wall St. Rank hold GSK as of Q3 2025.

  • Fox Run Management reported no remaining GSK position as of Q3 2025 after selling out during the quarter.
  • Fox Run Management sold 18,763 GSK shares in Q3 2025, an estimated $720K.
  • Fox Run Management first reported a position in GSK in Q2 2016 and held it in 17 quarters.
  • Fox Run Management's GSK position peaked at $1.46M in Q2 2024.
  • 895 funds tracked by Wall St. Rank held GSK as of Q3 2025.

Based on Fox Run Management's 13F filing for Q3 2025, filed 12 Nov 2025.